Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.515 USD | +0.77% | -10.84% | +132.65% |
05-13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
05-08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+132.65% | 607M | |
+28.92% | 48.16B | |
-0.39% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.94% | 25.59B | |
-22.81% | 18.96B | |
+8.89% | 12.92B | |
+30.09% | 12.03B | |
-1.71% | 11.77B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- HC Wainwright Adjusts Mind Medicine's Price Target to $5 From $10, Maintains Buy Rating